Login / Signup

The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status.

Nobuki FurubayashiAkinori MinatoTakahito NegishiNaotaka SakamotoYoohyun SongYoshifumi HoriToshihisa TomodaMirii HaradaShingo TamuraHiroki KobayashiYamato WadaKentaro KuroiwaNarihito SekiNaohiro FujimotoMotonobu Nakamura
Published in: OncoTargets and therapy (2022)
Pembrolizumab for advanced UC demonstrated similar changes in the eosinophil count, efficacy and toxicity in both older and younger patients. In patients with a poor PS, although toxicity was significantly lower, survival was significantly worse, and neither an increase in REC nor a decrease in NER were observed, but these values showed significant changes in patients with a good PS.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • oxidative stress
  • physical activity
  • ejection fraction
  • advanced non small cell lung cancer
  • community dwelling
  • middle aged
  • peritoneal dialysis